Curis, Inc.  

(Public, NASDAQ:CRIS)   Watch this stock  
Find more results for CRIS
2.27
-0.04 (-1.73%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.20 - 2.33
52 week 2.09 - 4.74
Open 2.32
Vol / Avg. 0.00/630,826.00
Mkt cap 195.10M
P/E     -
Div/yield     -
EPS -0.15
Shares 85.95M
Beta 1.97
Inst. own 56%
May 8, 2014
Q1 2014 Curis, Inc. Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 7, 2014
Curis, Inc. at Deutsche Bank Healthcare Conference - 4:50PM EDT - Add to calendar
Apr 9, 2014
Curis, Inc. at Needham Healthcare Conference
Apr 9, 2014
Curis, Inc. at Biotechnology Industry Organization Asia International Conference
Mar 11, 2014
Curis, Inc. at ROTH Conference
Mar 3, 2014
Curis, Inc. at Cowen Health Care Conference
Feb 26, 2014
Curis, Inc. at RBC Capital Markets Healthcare Conference
Feb 20, 2014
Q4 2013 Curis, Inc. Earnings Release
Feb 20, 2014
Q4 2013 Curis, Inc. Earnings Conference Call
Feb 12, 2014
Curis, Inc. at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -275.44% -82.14%
Operating margin -294.15% -62.77%
EBITD margin - -61.82%
Return on average assets -21.16% -16.39%
Return on average equity -38.82% -31.02%
Employees 33 -
CDP Score - -

Address

4 Maguire Road
LEXINGTON, MA 02421
United States - Map
+1-617-5036500 (Phone)
+1-617-5036501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).

Officers and directors

James R. McNab Jr. Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Ali Fattaey Ph.D. President, Chief Operating Officer
Age: 48
Bio & Compensation  - Reuters
Daniel R. Passeri J.D. Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Michael P. Gray Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jaye Viner M.D. Chief Medical Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Mani Mohindru Ph.D. Vice President - Corporate Strategy and Investor Relations
Bio & Compensation  - Reuters
Tania Chander Pharm.D. Vice President - Product Development
Bio & Compensation  - Reuters
Mark W. Noel Vice President - Technology Management and Intellectual Property
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kenneth J. Pienta M.D. Director
Age: 53
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 71
Bio & Compensation  - Reuters